When to Resume Direct Oral Anticoagulants Following Gastrointestinal Bleeding
Moe H. Kyaw,Francis K.L. Chan
DOI: https://doi.org/10.1016/j.cgh.2018.08.009
IF: 13.576
2018-01-01
Clinical Gastroenterology and Hepatology
Abstract:For more than half a century, warfarin has been used as a highly effective oral anticoagulant. However, warfarin requires regular monitoring and has interactions with multiple drugs and foods, making it inconvenient for both patients and their clinicians. Direct oral anticoagulants (DOACs), which are convenient to use, have surpassed warfarin as the anticoagulants of choice.1Loo S.Y. Dell'Aniello S. Huiart L. et al.Trends in the prescription of novel oral anticoagulants in UK primary care.Br J Clin Pharmacol. 2017; 83: 2096-2106Crossref PubMed Scopus (174) Google Scholar Although DOACs are reported to have improved safety compared with warfarin, the yearly incidence of gastrointestinal (GI) bleeding in DOAC users is still up to 3.2%.2Patel M.R. Mahaffey K.W. Garg J. et al.Rivaroxaban versus warfarin in nonvalvular atrial fibrillation.N Engl J Med. 2011; 365: 883-891Crossref PubMed Scopus (7203) Google Scholar With more than 3.5 million DOAC prescriptions written annually in the United States alone,3Nguyen E. White C.M. Patel M.R. et al.Doses of apixaban and rivaroxaban prescribed in real-world United States cardiology practices compared to registration trials.Curr Med Res Opin. 2016; 32: 1277-1279Crossref PubMed Scopus (24) Google Scholar GI bleeding associated with DOAC can be a significant burden. To date, there is a huge knowledge gap about the management of patients on DOACs complicated by GI bleeding. In this issue of Clinical Gastroenterology and Hepatology, Sengupta et al4Sengupta N. Marshall A.L. Jones B.A. et al.Rebleeding vs thromboembolism after hospitalization for gastrointestinal bleeding in patients on direct oral anticoagulants.Clin Gastroenterol Hepatol. 2018; 16: 1893-1900Abstract Full Text Full Text PDF PubMed Scopus (28) Google Scholar explored this important area on DOAC therapy after GI bleeding. In a retrospective cohort study, the investigators used medical claims data to identify a cohort of 1338 patients who were receiving DOACs and hospitalized with GI bleeding. Restarting DOACs within 30 days did not significantly increase the risk of recurrent GI bleeding or reduce the risk of thromboembolism. Patients who did not resume DOACs were older and sicker; were more likely to have heart failure, required more blood transfusions, and more intensive care. Although Sengupta et al4Sengupta N. Marshall A.L. Jones B.A. et al.Rebleeding vs thromboembolism after hospitalization for gastrointestinal bleeding in patients on direct oral anticoagulants.Clin Gastroenterol Hepatol. 2018; 16: 1893-1900Abstract Full Text Full Text PDF PubMed Scopus (28) Google Scholar are to be congratulated for tackling this largely unexplored area, we need to interpret the results with caution because of certain limitations in the study design. First, it was not possible to control for confounding factors such as the severity of index GI bleeding and the success of endoscopic treatment. In addition, residual confounding is always a concern in nonrandomized studies. Second, the accuracy of claims data is questionable, particularly on the use of DOACs at the time of index GI bleeding and their resumption after GI bleeding. Third, without predefined measures of end points, there will be inconsistencies in the measurement of bleeding and thrombotic outcomes. How should we manage DOACs in the setting of acute GI bleeding? A question often asked by clinicians, yet guidelines provide little to no recommendations.5Gralnek I.M. Dumonceau J.M. Kuipers E.J. et al.Diagnosis and management of nonvariceal upper gastrointestinal hemorrhage: European Society of Gastrointestinal Endoscopy (ESGE) Guideline.Endoscopy. 2015; 47: a1-a46Crossref PubMed Scopus (497) Google Scholar Expert opinions primarily are built on our knowledge about the pharmacokinetic properties of DOACs rather than on direct data from DOAC users with GI bleeding.6Chan F.K.L. Goh K.L. Reddy N. et al.Management of patients on antithrombotic agents undergoing emergency and elective endoscopy: joint Asian Pacific Association of Gastroenterology (APAGE) and Asian Pacific Society for Digestive Endoscopy (APSDE) practice guidelines.Gut. 2018; 67: 405-417Crossref PubMed Scopus (86) Google Scholar Management of acute GI bleeding associated with DOACs depends on the severity of bleeding, timing of the last dose of DOAC, creatinine clearance,7Fountzilas C. George J. Levine R. Dabigatran overdose secondary to acute kidney injury and amiodarone use.N Z Med J. 2013; 126: 110-112PubMed Google Scholar and hepatic function.8Kubitza D. Roth A. Becka M. et al.Effect of hepatic impairment on the pharmacokinetics and pharmacodynamics of a single dose of rivaroxaban, an oral, direct Factor Xa inhibitor.Br J Clin Pharmacol. 2013; 76: 89-98Crossref PubMed Scopus (142) Google Scholar For non–life-threatening bleeding in the absence of renal or hepatic impairment, the anticoagulant effect of DOACs wanes off after discontinuation (over 12–24 hours) and a temporary cessation of DOAC is probably sufficient without the need for reversal. In other circumstances, one may consider oral charcoal if a DOAC was taken within 2 to 3 hours, but supporting evidence is limited to a single in vitro study.9van Ryn J. Sieger P. Kink-Eiband M. Adsorption of dabigatran etexilate in water or dabigatran in pooled human plasma by activated charcoal in vitro.Blood. 2009; 114: 1065Google Scholar There is no evidence for the use of vitamin K or fresh-frozen plasma for reversing the effects of DOACs. Prothrombin complex concentrate may be considered, but evidence is available only from healthy volunteers without bleeding.10Eerenberg E.S. Kamphuisen P.W. Sijpkens M.K. et al.Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects.Circulation. 2011; 124: 1573-1579Crossref PubMed Scopus (1265) Google Scholar, 11Escolar G. Fernandez-Gallego V. Arellano-Rodrigo E. et al.Reversal of apixaban induced alterations in hemostasis by different coagulation factor concentrates: significance of studies in vitro with circulating human blood.PLoS One. 2013; 8: e78696Crossref PubMed Scopus (113) Google Scholar Hemodialysis may reverse the anticoagulant effect of dabigatran owing to the low protein-binding nature of this drug,12Stangier J. Rathgen K. Stahle H. et al.Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: an open-label, parallel-group, single-centre study.Clin Pharmacokinet. 2010; 49: 259-268Crossref PubMed Scopus (642) Google Scholar but may not be effective with other DOACs, which are highly protein-bound.13Ieko M. Naitoh S. Yoshida M. et al.Profiles of direct oral anticoagulants and clinical usage-dosage and dose regimen differences.J Intensive Care. 2016; 4: 19Crossref PubMed Scopus (38) Google Scholar We rely on idarucizumab as the only antidote currently available (for dabigatran) and approved by the US Food and Drug Administration, yet its clinical applicability is questionable because the data come from a single study.14Pollack Jr., C.V. Reilly P.A. van Ryn J. et al.Idarucizumab for dabigatran reversal - full cohort analysis.N Engl J Med. 2017; 377: 431-441Crossref PubMed Scopus (670) Google Scholar There are no direct data to guide when to resume DOACs after GI bleeding. Neither American nor European guidelines provide clear guidance on this clinical dilemma. Recently, the Asian Pacific Association of Gastroenterology and the Asian Pacific Society for Digestive Endoscopy jointly issued a guideline on when to resume DOACs after GI bleeding. They recommend resuming a DOAC by day 3 once hemostasis is achieved, and without bridging therapy.6Chan F.K.L. Goh K.L. Reddy N. et al.Management of patients on antithrombotic agents undergoing emergency and elective endoscopy: joint Asian Pacific Association of Gastroenterology (APAGE) and Asian Pacific Society for Digestive Endoscopy (APSDE) practice guidelines.Gut. 2018; 67: 405-417Crossref PubMed Scopus (86) Google Scholar Their recommendation is based on the fact that DOACs have a short half-life (approximately 12 h) in patients with normal renal clearance, and the residual anticoagulant effect will be minimal after 3 days of discontinuation. Bridging therapy is not necessary because these drugs have a rapid onset of action (between 1 and 4 h). Should we switch to another anticoagulant after GI bleeding? In the 4 phase III trials comparing the 4 different DOACs against warfarin (Randomized Evaluation of Long-Term Anticoagulation Therapy, Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation, Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation trial, and Effective Anticoagulation with Factor Xa Next Generation in Atrial Fibrillation -Thrombolysis in Myocardial Infarction 48),2Patel M.R. Mahaffey K.W. Garg J. et al.Rivaroxaban versus warfarin in nonvalvular atrial fibrillation.N Engl J Med. 2011; 365: 883-891Crossref PubMed Scopus (7203) Google Scholar, 15Connolly S.J. Ezekowitz M.D. Yusuf S. et al.Dabigatran versus warfarin in patients with atrial fibrillation.N Engl J Med. 2009; 361: 1139-1151Crossref PubMed Scopus (8888) Google Scholar, 16Granger C.B. Alexander J.H. McMurray J.J. et al.Apixaban versus warfarin in patients with atrial fibrillation.N Engl J Med. 2011; 365: 981-992Crossref PubMed Scopus (6709) Google Scholar, 17Giugliano R.P. Ruff C.T. Braunwald E. et al.Edoxaban versus warfarin in patients with atrial fibrillation.N Engl J Med. 2013; 369: 2093-2104Crossref PubMed Scopus (3584) Google Scholar apixaban was the only DOAC that was not associated with an increased risk of major GI bleeding. The other 3 DOACS had a significantly higher risk of major GI bleeding compared with warfarin. This finding was supported by a recent observational study of more than 13,000 patients, in which apixaban was associated with a lower risk of GI bleeding than dabigatran (hazard ratio, 0.39; 95% CI, 0.27–0.58; P < .001) or rivaroxaban (hazard ratio, 0.33; 95% CI, 0.22–0.49; P < .001).18Abraham N.S. Noseworthy P.A. Yao X. et al.Gastrointestinal safety of direct oral anticoagulants: a large population-based study.Gastroenterology. 2017; 152: 1014-1022.e1Abstract Full Text Full Text PDF PubMed Scopus (148) Google Scholar It must be noted that neither the cohort study nor the large phase III clinical trials were representative of patients who were restarting DOACs after an episode of GI bleeding. Thus, choosing apixaban over other DOACs after GI bleeding has yet to be investigated. What is the risk for thrombosis when DOACs are interrupted? DOACs are indicated for patients with atrial fibrillation or venous thromboembolism, but not for patients with mechanical heart valves. The only direct evidence on interruption interval of DOACs and thrombotic rates comes from a prospective open-label study that assessed idarucizumab for reversing the anticoagulant effect of dabigatran for patients who had uncontrolled bleeding or were about to undergo an urgent procedure. Twenty-four of the 403 patients (4.8%) developed a thrombotic event within 30 days after reversal treatment and 34 patients (6.8%) within 90 day after treatment.14Pollack Jr., C.V. Reilly P.A. van Ryn J. et al.Idarucizumab for dabigatran reversal - full cohort analysis.N Engl J Med. 2017; 377: 431-441Crossref PubMed Scopus (670) Google Scholar We are in urgent need of studies that will guide us in the management of DOACs after GI bleeding. This current study in Clinical Gastroenterology and Hepatology provides evidence to suggest that resumption of DOACs is safe after GI bleeding, but further prospective studies are required to confirm these findings. The best evidence will come from randomized trials. Until then, we rely on our belief or judgment of what little evidence is available. Rebleeding vs Thromboembolism After Hospitalization for Gastrointestinal Bleeding in Patients on Direct Oral AnticoagulantsClinical Gastroenterology and HepatologyVol. 16Issue 12PreviewLittle is known about outcomes of patients hospitalized for gastrointestinal bleeding (GIB) while they are taking direct oral anticoagulants (DOAC). We aimed to determine the frequency at which patients resume DOAC therapy following hospitalization for GIB in a real-world setting, and the risks and benefits. Full-Text PDF